MilliporeSigma’s chief executive officer, Udit Batra, was named “CEO of the Year” for 2016 by CPhI Pharma.

The company also won two CPhI Pharma Awards—one for excellence in excipients and formulation development and another for regulatory procedures and compliance. CPhI announced the awards at the organization’s annual awards gala on Oct. 4 in Barcelona, Spain.

“As advances in drug discovery yield more complex therapies, drug development and manufacturing must innovate at even a faster pace,” said Mr. Batra. “At MilliporeSigma, we will continue to empower researchers and scientists with solutions that improve drug development quality and efficiency, helping them solve their toughest problems. On behalf of the company, I am honored to receive this award.”

The CPhI Pharma Awards also acknowledged MilliporeSigma’s groundbreaking innovations in technology, formulation, regulatory procedures and product development. The company received the following technology awards:

Parteck SRP 80 won for “Excipients and Formulation Development.” Parteck SRP 80 is a functional direct compressable excipient designed for oral sustained-release formulations. It is fully synthetic for batch-to-batch and performance consistency and enhances the bioavailability of actives.

The Emprove program won for “Regulatory Procedures and Compliance.” The program provides documentation and regulatory information on materials used in the manufacture of drug products. This information enhances transparency, facilitates manufacturers’ risk assessment workflows and supplier qualification.